Company
A pharmaceutical company since 1958.
Anstalt für Zellforschung develops, quality-assures and commercialises pharmaceuticals, OTC and consumer-health products from Vaduz, Liechtenstein.
We are both a brand owner and an operating partner: three brands across two product regimes, plus market-access and commercial capabilities for selected partner products.
- 1958
- founded in Vaduz, Liechtenstein
- More than 16 million
- products sold across own brands — company figures
- 6
- active countries; accessible in 22+ through distribution partners
- More than 2 million
- patients supported — company estimate
About AFZ
Six decades in market. Sixteen million products sold.
For over six decades we have brought pharmaceuticals, OTC and consumer-health products to market — as brand owner, quality partner and commercial operator. The company began as a cell-research institute; the scientific orientation still sets how we assess a formulation before we agree to carry it.
Today AFZ combines an operating brand portfolio with market-access, regulatory and commercial capabilities across Europe, partner and registration activities in Ecuador and Bolivia, and commercial development in Mexico — with products accessible in more than 22 countries through distribution partnerships.
We are extremely proud of the pioneering company we have created. For over 60 years we have successfully developed and distributed medical products to serve our patients worldwide.
Mission & values
Helping people stay in good health.
Good health means more than avoiding severe illness or hospitalisation. It also means the health-related problems people face in their daily lives are addressed, treated and prevented.
We own and commercialise a range of documented and trusted brands within key categories of everyday healthcare. Within each category, we guide people to relevant choices and help them select the product that will prevent or manage the issue they are experiencing.
We want to give people control over their daily healthcare. By empowering them to make smarter choices, we believe we can increase their quality of life.
-
01
Individuality
Every patient is unique — their needs, their way of life and their expectations differ. Medicinal products should be formulated to meet individual needs rather than fit a universal pain point, which is why we pinpoint the physical origin of a complaint before we formulate against it.
-
02
For a better world
More than a billion people worldwide have no access to basic medical supplies. Supporting disadvantaged communities is rooted in our corporate values: we donate essential medicinal products where they are needed to fight treatable conditions.
How we operate.
Two roles, one system — which is why the advice matches the practice.
-
Brand owner
The AFZ portfolio includes Nervinetten® / Nervinetas®, EMASEX® and Zellaforte®. Current regulatory and commercial roles are stated product by product and market by market.
See the portfolio -
Operating partner
The same product experience supports partner work in market access, regulatory coordination, quality processes and commercialisation — under contract, with responsibilities fixed in writing.
See the services
Milestones
From 1958 to today.
-
1958
Anstalt für Zellforschung founded in Vaduz
Established by Wolf Georg Freiherr von Bernewitz with the registered purpose of researching, manufacturing and distributing biological products, and administering patents and licences.
Source: Commercial register FL-0001.009.294-9, entry of 7 August 1958
-
1958
Zellaforte® begins
The longevity brand starts in the company’s first year, carrying the founders’ cell-research work into products people could take every day — decades before longevity became a category.
Source: Company records
-
1978
EMASEX® enters the market
The men’s and women’s health brand enters pharmacy distribution and becomes a long-standing name in the German-speaking markets.
Source: Company records
-
1980s
International expansion into Latin America and North America
Business develops across LATAM countries, Mexico and the USA. The portfolio of the period includes Nervinetten®, Emasex-N and Zellaforte Diabetes.
Source: Company history, zellforschung.com
-
2016
Acquisition by Zellaforte Pharma Holding GmbH
The company changes ownership, relaunches products and enters new international markets. The statutes are renewed on 3 June 2016.
Source: Company history + commercial register, statutes dated 03.06.2016
-
2019
Trogen branch opens
A Swiss branch office opens in Trogen, Appenzell Ausserrhoden.
Source: Swiss commercial-register branch entry, 2019
-
2026
Zellaforte® portfolio relaunch
The Zellaforte® portfolio returns with KeraBiotic® as its current active product.
Source: AFZ portfolio records, August 2026
Operating principles.
Four principles guide product, quality and commercial decisions.
-
Patient and consumer protection
Product quality, approved use and regulatory obligations take precedence over commercial timelines.
-
Own what we sell
We run our own brands through the same system we offer partners.
-
Say what is authorised
No claim leaves this building that the regulation does not permit.
-
Long horizons
Six decades of continuous operation is a decision, not an accident.
Locations.
Headquarters in Liechtenstein, operations in eastern Switzerland.
-
Headquarters
Vaduz, Liechtenstein
Zollstrasse 34 · 9490 Vaduz
+423 232 26 17 · info@zellforschung.liCompany management, regulatory affairs, portfolio and commercial activities.
-
Operations
Trogen, Switzerland
Landsgemeindeplatz 6 · 9043 Trogen AR
Quality & distribution operationsRegistered as Anstalt für Zellforschung, Vaduz (LI), Zweigniederlassung Trogen. Product- and market-specific roles are confirmed in the relevant partner documentation.
Quality & Compliance
Product quality, scope and responsibilities.
Review the control areas, product regimes and due-diligence routes used to document quality responsibilities around AFZ and partner products.
Want to work with us — or for us?
Partnerships, licensing and market access, or an open position in Vaduz.